Market Place
Sourcing Support
Geron Corporation Announces $375M in Funding with Royalty Pharma
07 Nov 2024 //
BUSINESSWIRE
Syndax strikes $350M funding deal with Royalty Pharma
06 Nov 2024 //
FIERCE PHARMA
Syndax & Royalty Pharma Enter $350M Niktimvo™ Royalty Deal
04 Nov 2024 //
PR NEWSWIRE
Ascendis Pharma, Royalty Pharma Enter $150M Royalty Funding Agreement
03 Sep 2024 //
GLOBENEWSWIRE
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
28 Aug 2024 //
PRESS RELEASE
Royalty Pharma Reports Second Quarter 2024 Results
08 Aug 2024 //
PRESS RELEASE
Royalty Pharma Appoints Molly Sawaya as Executive Vice President
24 Jul 2024 //
PRESS RELEASE
Royalty Pharma To Announce Second Quarter 2024
19 Jul 2024 //
PRESS RELEASE
Royalty Pharma Declares Third Quarter 2024 Dividend
17 Jul 2024 //
PRESS RELEASE
Agios cashes in on cancer drug again with $905M Royalty Pharma deal
28 May 2024 //
BIOPHARMADIVE
Cytokinetics secures up to $575M in royalty deal, frustrating investors
24 May 2024 //
BIOPHARMADIVE
Cytokinetics, Royalty Pharma Expand Collaboration Up To $575M
22 May 2024 //
GLOBENEWSWIRE
Royalty Pharma pays startup $525M for stake in Sanofi MS drug
10 May 2024 //
BIOPHARMADIVE
Royalty Pharma Announces Dividend Increase
19 Jan 2024 //
PRESS RELEASE
Royalty Pharma Highlights Accomplishments
08 Jan 2024 //
PRESS RELEASE
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
13 Nov 2023 //
BUSINESSWIRE
PTC Announces Evrysdi Agreement with Royalty Pharma for Up To $1.5 Billion
20 Oct 2023 //
PR NEWSWIRE
Royalty Pharma Declares Fourth Quarter 2023 Dividend
16 Oct 2023 //
PRESS RELEASE
Royalty Pharma To Announce Third Quarter 2023 Financial Results
11 Oct 2023 //
PRESS RELEASE
Royalty Pharma Appoints Eric Schneider As Chief Technology Officer
21 Sep 2023 //
PRESS RELEASE
Royalty Pharma To Present At Upcoming Investor Conferences
05 Sep 2023 //
PRESS RELEASE
Ascendis and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
05 Sep 2023 //
GLOBENEWSWIRE
Royalty Pharma to Pay Potential $500M for Royalties on Ferring’s Gene Therapy
25 Aug 2023 //
BIOSPACE
Royalty Pharma to Present at Goldman Sachs 44th Annual Healthcare Conference
07 Jun 2023 //
PRESS RELEASE
PureTech and Royalty Enter into KarXT Royalty Agreement for up to $500 Million
23 Mar 2023 //
BUSINESSWIRE
Royalty swoops in with $100M upfront for slice of Karuna`s KarXT
23 Mar 2023 //
FIERCE BIOTECH
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
17 Mar 2023 //
ENDPTS
Royalty Pharma To Announce Q4 And Full Year 2022 Financial Results
18 Jan 2023 //
PRESS RELEASE
Royalty Pharma Acquires Ionis` Royalty In Spinraza, Pelacarsen For $1.1 Bln
10 Jan 2023 //
PR NEWSWIRE
Royalty Pharma Provides Business Update At 41St Annual J.P. Morgan Conference
09 Jan 2023 //
PRESS RELEASE
Royalty Pharma Announces Dividend Increase
09 Jan 2023 //
PRESS RELEASE
Royalty Pharma To Present At The J.P. Morgan Healthcare Conference On January 9
04 Jan 2023 //
PRESS RELEASE
HealthCare Royalty pays Atara $31M cash for a piece of cell therapy royalties
21 Dec 2022 //
ENDPTS
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement
20 Dec 2022 //
BUSINESSWIRE
Amgen`s PIII cardio plan takes shape, Royalty Pharma snags stake in future sales
09 Nov 2022 //
ENDPTS
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
Royalty Pharma Declares Third Quarter 2022 Dividend
15 Jul 2022 //
PRESS RELEASE
Theravance, Ultragenyx sell royalties for $1.8B
15 Jul 2022 //
FIERCEPHARMA
Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022
14 Jul 2022 //
PRESS RELEASE
Innoviva Sells 15% Stake in Theravance Respiratory Co. to Royalty Pharma
13 Jul 2022 //
BUSINESSWIRE
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma
13 Jul 2022 //
PRNEWSWIRE
Royalty Pharma and Jefferies Invest $111M in ApiJect
19 May 2022 //
CONTRACTPHARMA
Cytokinetics, Royalty partner on heart failure drug for $450M
08 Jan 2022 //
ENDPTS
Biogen acquires rights for potential Actemra biosimilar; Royalty buys lumasiran
08 Apr 2021 //
ENDPTS
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
01 Apr 2021 //
GLOBENEWSWIRE
Royalty gets more competition as a private equity firm launches $725M
19 Feb 2021 //
ENDPTS
Minerva and Royalty Announce Sale of Seltorexant Royalty for up to $155M
19 Jan 2021 //
BIOSPACE
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon
03 Nov 2020 //
GLOBENEWSWIRE
XOMA Acquires Royalty Interest Four Lysosomal Storage Disorder Enzymes Developed
03 Nov 2020 //
BIOSPACE
Biohaven and Royalty Pharma Announce Funding Agreement
08 Aug 2020 //
PRESS RELEASE
